#United States #St. Petersburg #Buck Institute #Attilio #Dr. Verdin

Dr. Eric Verdin Appointed Co-Chairman of Attilio

In an exciting development for the aging research and healthcare community, Dr. Eric Verdin, the esteemed President and CEO of the Buck Institute for Research on Aging, has been named Co-Chairman of Attilio. This strategic appointment, announced on October 16, 2026, positions Attilio at the forefront of longevity science, benefiting from Dr. Verdin's extensive insights and experience in advancing research around aging and longevity.

The Buck Institute, founded in Novato, California, is recognized as the world's first independent biomedical research institute dedicated solely to the investigation of aging and related diseases. Since its inception, it has played a pivotal role in legitimizing the field of geroscience and has been instrumental in numerous groundbreaking discoveries that have expanded our understanding of aging biology. Dr. Verdin has not only led this innovative institute but has also engaged directly with the public and policymakers, advocating for the scientific advancement of aging research and its implications for healthier, longer lives.

As Co-Chairman at Attilio, which operates as a Human powered AI Life Optimization Platform™, Dr. Verdin will provide unparalleled access to the cutting-edge research and methodologies utilized at the Buck Institute. This entails leveraging crucial biomarkers, advanced imaging technology, and clinical protocols that have been developed to study the aging process in humans. By integrating this wealth of scientific knowledge into the care structure at Attilio, Dr. Verdin will help refine the approach to longevity for its members, ensuring that they benefit from only the most effective and rigorously tested interventions that aim to extend their healthy life spans.

Dr. Verdin has also conceptualized the Dr. Verdin Baseline Assessment™, an innovative program offered by Attilio which members can access for $2,500. This assessment is designed to evaluate individual health profiles and recommend tailored strategies aimed at enhancing longevity and healthspan.

In addition to his leadership role, Dr. Verdin will headline Attilio's inaugural Longevity Event, scheduled for October 29 and 30, 2026, at both Stanford University and the Buck Institute. The event features a distinguished lineup of experts, including Dr. Laura Carstensen, Dr. Robert Waldinger from Harvard Medical School, and Dr. Dean Ornish, underscoring the importance of collaborative dialogue in the field of longevity research.

The mission of Attilio, as articulated by its CEO and Founder, Paul A. Pagnato, is to democratize access to a quality lifespan exceeding 100 years for over 99% of the U.S. population. With Dr. Verdin's involvement, Attilio can significantly enhance its impact, aligning innovative health strategies with real-world applications.

Attilio has established itself as a platform committed to transparency and integrity, adhering to Conflict-Free Standards™ that ensure no commissions, revenue sharing, or self-dealing in the services it provides. Launched in September 2026, the company is dedicated to collaborating with leading experts from premier institutions such as Stanford, Harvard, and the Buck Institute to redefine health optimization through technology.

In summary, Dr. Eric Verdin’s appointment as Co-Chairman of Attilio marks a significant milestone in the intersection of aging research and practical health solutions. His contribution is expected to reshape how individuals approach health and longevity, leading to more informed, science-based decisions concerning aging, all while fostering an inclusive approach to health technology and longevity.